Recombinant human growth hormone treatment in children with thalassemia major
Pediatrics International, cilt.41, sa.6, ss.655-661, 1999 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 41 Sayı: 6
- Basım Tarihi: 1999
- Doi Numarası: 10.1046/j.1442-200x.1999.01139.x
- Dergi Adı: Pediatrics International
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.655-661
- Anahtar Kelimeler: Growth hormone, Growth retardation, Thalassemia
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: To evaluate the growth hormone reserve and the growth hormone response to recombinant human growth hormone (GH) in prepubertal thalassemic children with growth retardation. Methods: Twenty thalassemic patients with short stature and delayed bone age were studied. Patients were randomized into GH-treated (n = 10) and non-GH treated (control; n = 10) groups. The GH-treated group received recombinant human (rh)-GH (Genotropin) at the dose of 0.7 IU/kg per week for 12 months. Results: There was a significant discordance between GH response to pharmacologic stimuli and physiological secretion of GH/GHRH testing. Following the administration of rhGH, growth velocity increased from 2.47 ± 0.48 cm/year to 6.27 ± 0.76 cm/year (P = 0.005), whereas there was not a similar change in the non-GH- treated group. The height velocities of the two groups during the 1 year follow-up period were significantly different (6.27 ± 0.76 vs 3.99 ± 0.34 cm/year; P = 0.025). There were significant differences between the height velocity improvements and height velocity standard deviation scores of the two groups as well. Conclusion: The present study has demonstrated that rhGH is a safe and efficacious mode of treatment in thalassemic children.